Recurrent Small Cell Lung Cancer (SCLC) Terminated Phase 2 Trials for Temozolomide (DB00853)

Also known as: Recurrent Small-cell Lung Cancer (SCLC) / Recurrent Small Cell Lung Cancer / Refractory Small cell lung cancer / Small Cell Lung Cancer Recurrent

IndicationStatusPhase
DBCOND0122754 (Recurrent Small Cell Lung Cancer (SCLC))Terminated2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02477813Temozolomide in Patients Affected by Relapsed Sensitive or Refractory Small Cell Lung Cancer With MGMT MethylationTreatment